Replies to post #225489 on Biotech Values

[linhdtu]

enta has a long way to go in hbv. do you think any single drug regimen has a passing chance of curing hep b? i don't think so. that said, i'm a great believer in proving single agent efficacy before any combo attempt

[DewDiligence]

ENTA/ASMB—Shanghai Zhimeng Biopharma is another company developing an HBV “core” inhibitor (a/k/a CpAM):

https://www.clinicaltrials.gov/ct2/show/NCT04220801